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Abstract
Dengue is the most important vector-borne dis-
ease in the Americas and threatens the lifes of 
millions of people in developing countries. Im-
precise morbidity and mortality statistics under-
estimate the magnitude of dengue as a regional 
health problem. As a result, it is considered a 
low priority by the health sector with no timely 
steps for effective control. Dengue is perceived as 
a problem of "others" (individually, collectively 
and institutionally), therefore responsibility for 
its control is passed on to others (neighbors, the 
community, municipality, health institutions, or 
other governmental agencies). With no precise 
risk indicators available there is little opportu-
nity for timely diagnoses, treatment, health in-
terventions or vector control (poor surveillance). 
Solutions only targeting the vector reduce the im-
pact of interventions and there is no sustainable 
control. Without political commitment there are 
insufficient resources to face the problem. This 
paper discusses the challenges for prevention 
and control in the Americas. 
Dengue; Communicable Disease Control; Dis-
ease Prevention
Introduction
Dengue is now the most important vector-borne 
disease in the Americas and threatens the health 
of millions of people that live in urban, subur-
ban and rural environments. Clinical and public 
health services have been unable to diminish this 
disease since there is no vaccine available to pre-
vent infection, no effective medical treatments 
that avert the development of severe symptoms 
and no sustainable control measures against the 
vector that guarantee protection of affected com-
munities. 
Dengue was initially identified as breakbone 
fever in 1790 in Philadelphia, U.S.A 1, and later 
spread throughout the Americas, until the Pan 
American Health Organization (PAHO) launched 
an Aedes aegypti eradication campaign to com-
bat yellow fever in the 1950s and 1960s that came 
close to eliminating the vector from the conti-
nent 2. Although the geographical distribution of 
the vector is similar to its distribution before the 
eradication campaigns 3, populations during the 
“eradication era” were principally rural. In the last 
40 years, there has been intensive urbanization 
due to massive migration from agricultural areas 
to cities. Although urbanization in Latin America 
and the Caribbean had already reached 41% of 
the population by 1950, the population living in 
urban areas is expected to reach between 82 and 
84% by 2030; by then the Latin America and Car-
ibbean region will be the second most urbanized 
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in the world 4. The current distribution of dengue 
vectors in the Americas is a fraction of their po-
tential niche, especially with deteriorating social, 
environmental and economic conditions that 
have made vector control a more challenging 
goal nowadays than it was in the past. 
Traditional approaches to dengue prevention 
and control have been inherited from the verti-
cal programs that targeted vector elimination in 
domestic habitats, with the use of larvicides and 
insecticides in addition to breeding site elimina-
tion as the core of Aedes control strategies. The 
initial impact of the eradication campaign cre-
ated the false impression that any vector control 
strategy could achieve similar reductions. During 
the 1990s Ae. aegypti control programmes shifted 
from large-scale spraying to community-based 
programmes, mainly due to the decentralization 
of health services, the breakdown of vertical con-
trol programs in the region and the lack of tech-
nical personnel. Failure to reduce efficiently vec-
tor densities have given way to the development 
and application of innovative approaches for 
community involvement, although with limited 
impact in the control of the overall spectrum of 
breeding sites in the household and peridomes-
tic surroundings 5,6. The purpose of this review 
is to describe the challenges faced by prevention 
and control programs in addressing a major sani-
tary health problem in the region. 
Dengue in numbers
Dengue is the most widely distributed viral he-
morrhagic fever in the world 7,8. In the 1950s, 
only nine countries reported dengue, while to-
day more than 100 countries worldwide with a 
combined population of more than 2.5 billion 
are at risk of dengue infection. The average 
number of cases reported yearly to the World 
Health Organization (WHO) rose from 908 dur-
ing the 1950s to 514,139 in the 1990s 9. Around 
50 million cases are estimated to occur each year 
causing an average 24,000 deaths worldwide, 
and a 100% increase is predicted in the com-
ing two to three decades 10. During the 1980s 
an average 91,000 cases were reported annually 
by 25 countries. During the period from 2000 to 
2006, an average of 545,000 cases was reported 
every year by 44 countries. Dengue statistics 
should be considered a proxy for real incidence. 
The upward trend and cyclical nature of dengue 
epidemics every three to five years, occurs at dif-
ferent moments in every country (Table 1). Al-
though epidemic outbreaks are not temporally 
homogenous, reintroductions from one country 
to another also provoke increases in the risk of 
severe dengue infection 11. The first major den-
gue hemorrhagic epidemic in the Americas oc-
curred in Cuba in 1981 and was caused by den-
gue 2 virus. From 1981 to 1996, 42,246 dengue 
Table 1  
Dengue incidence (rates per 100,000 inhabitants) in selected countries, 2000-2006.
 Country 2000 2001 2002 2003 2004 2005 2006
 Argentina 4.6 0.03 0.6 0.4 8.7 0.1 0.5
 Bolivia 0.88 14.7 74.3 327.4 369.5 222.1 102.0
 Brazil 136.1 239.4 452.4 198.1 65.4 118.1 200.8
 Colombia 53.8 272.7 210.3 258.7 135.4 149.9 180.7
 Costa Rica 434.6 818.2 314.5 606.3 290.0 1,165.2 345.1
 Cuba 1.2 101.6 26.7 0 0 0.7 ?
 Dominican Republic  40.7 42.3 37.6 72.5 27.6 33.7 72.3
 Ecuador 181.4 84.8 45.3 80.1 47.8 94.2 45.1
 El Salvador 51.7 17.1 286.0 116.2 201.0 226.3 307.8
 Guatemala 79.1 38.6 65.0 57.8 54.3 54.3 24.5
 Honduras 210.4 138.0 490.8 251.8 303.7 286.6 128.3
 Mexico 21.9 6.2 9.8 5.0 8.2 16.8 27.2
 Nicaragua 144.2 40.4 41.4 53.7 19.9 31.6 25.9
 Panama 11.1 53.3 24.5 10.1 12.9 137.9 145.6
 Paraguay 441.8 0.7 33.2 2.4 2.9 7.2 75.8
 Peru 21.4 89.4 34.0 13.9 37.5 24.4 14.2
 Puerto Rico 62.9 132.4 73.5 94.5 83.2 144.3 77.0
 Venezuela 87.3 337.7 152.9 109.6 124.6 171.3 149.9
Source: Pan American Health Organization. http://www.paho.org/spanish/ad/dpc/cd/Dengue.htm (accessed on Feb/2007).
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hemorrhagic fever cases were reported in sev-
eral countries, although 90% of these cases were 
from Venezuela (52%), Cuba (24%), Colombia 
(9%), Nicaragua (6%) and Mexico (3%). During 
the 2000-2006 period, 85,331 dengue hemor-
rhagic fever cases were reported from Colombia 
and Venezuela (61%), while 16% of cases were 
from Mexico (Table 2). 
Although there is an overall ratio of 45 den-
gue fever cases reported for every dengue hem-
orrhagic fever case detected, the ratio of dengue 
/dengue hemorrhagic fever cases reported in 
Brazil (468) and Costa Rica (396) is very different 
from those reported in Honduras (17), Venezuela 
(13), Colombia (10) or Mexico (7). This variation 
is principally due to under-reporting of dengue 
cases in the countries with the lowest dengue/ 
dengue hemorrhagic fever ratio and/or lack of 
severe dengue diagnosis in the countries with 
high ratios. In both scenarios, passive surveil-
lance of dengue fever cases and failure of clinical 
diagnostic capacity hamper precise measure-
ments of the magnitude and trend of this health 
problem and illustrate the problems faced by all 
surveillance systems: incomplete, inopportune 
and imprecise information (Table 2).
A practical framework for prevention 
and control
Dengue epidemiology has changed with time 
and the evolving clinical picture, social and cul-
tural environments, vector control strategies and 
surveillance capabilities in the region must be 
addressed in an integrated manner, due to the 
complexity of factors involved in transmission 
dynamics, risk assessment and control potential. 
The purpose of the present framework (Table 3) 
is to describe what we know about dengue, the 
challenges associated with major transmission 
determinants, the problems faced by clinicians 
for dengue diagnosis and treatments of compli-
cations; the laboratory infrastructure required to 
support clinicians and public health workers, the 
inconveniences faced by surveillance systems, 
and the unmet needs of prevention and control 
strategies. 
Table 2  
Dengue hemorrhagic fever cases in selected countries, 2000-2006.
 Country 2000 2001 2002 2003 2004 2005 2006 Total Dengue fever/
          dengue hemorrhagic
          fever ratio
 Argentina 0 0 0 0 0 0 0 0 0
 Bolivia 73 0 1 47 25 10 1 157 137,3
 Brazil 59 679 2,607 713 77 433 628 5,196 467,7
 Colombia 1,819 6,563 5,269 4,878 2,815 4,306 5,379 31,029 9,8
 Costa Rica 4 37 27 69 11 52 64 264 395,7
 Cuba 0 69 12 0 0 0 ? 81 180,9
 Dominican Republic 58 4 76 252 136 84 230 840 33,2
 Ecuador 3 55 158 416 64 334 173 1,203 61,8
 El Salvador 411 54 405 138 154 207 245 1,614 50,1
 Guatemala 42 4 47 22 39 32 4 190 228,6
 Honduras 314 431 863 458 2,345 1,795 636 6,842 17,4
 Mexico 50 191 1,429 1,419 1,959 4,255 4,477 13,780 6,9
 Nicaragua 636 458 157 235 93 177 52 1,808 10,2
 Panama 3 7 5 0 4 2 5 26 287,1
 Paraguay 0 0 0 0 0 0 0 0 0
 Peru 0 251 13 15 35 16 4 334 188,6
 Puerto Rico 24 36 23 5 11 19 7 125 210,7
 Venezuela 2,186 6,541 2,979 2,246 1,986 2,681 2,476 21,095 13,4
 Americas 5,667 15,500 14,374 10,994 9,810 14,557 14,429 85,331 44.8
Source: Pan American Health Organization. http://www.paho.org/spanish/ad/dpc/cd/Dengue.htm (accessed on Feb/2007).
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Major determinants of dengue 
transmission
Environmental
Dengue is considered a disease of the tropics due 
to its most recent geographic distribution, de-
spite the fact that Ae. aegypti and breakbone fever 
were originally reported in temperate areas such 
as Philadelphia in the late 18th century. The per-
ception of dengue as a tropical disease derives 
from its relationship with climate variables such 
as heavy rainfall, high temperatures, humidity 
and vegetation, which define the vector’s eco-
logical niche and are typically found in South-
east Asian countries where dengue and dengue 
hemorrhagic fever were initially recognized. The 
vector is extremely sensitive to meteorological 
conditions and seasonal variations which affect 
its distribution and abundance in predictable 
annual cycling. Temperature influences dengue 
transmission by affecting vector density patterns, 
blood feeding habits and virus propagation in the 
mosquito 12,13.
Seasonal occurrence of dengue transmission 
can be attributed to the increase in breeding sites 
available during the rainy season or the need to 
accumulate water during droughts or dry sea-
sons 14. While these factors influence the density, 
productivity and stability of larval sites, its as-
sociation with transmission patterns usually lags 
several weeks 15,16. Global climate changes have 
created great concern about the emergence of 
dengue in more temperate areas (with controver-
sial conclusions), although predictions of dengue 
outbreaks in regions now free of the transmis-
sion, remain to be validated 17,18.
Table 3  
Practical framework for dengue prevention and control.
 Primary determinants    Health services determinants
 Environmental Biological  Clinical picture Risk  Diagnosis Treatment Surveillance Prevention
  risk factors  perception     and control
 Physical: temperature,  Vector:  Asymptomatic Other Null Null Not perceived Infestation
 rainfall, altitude,  competence  health needs   silent indices
 vegetation, soil use/ and capacity/     transmission (opportunity &
 Global: urbanization,  Virus: serotypes,      productivity)
 population growth,  virulence, Febrile Common Very low Self Poorly recognized. Breeding site
 migration; travel,  sequence of  disease self  medication Passive detection classification,
 industry responsibility  infections/  limiting  analgesics  Source reduction;
 (non-recyclable  Host: age, sex,      chemical, 
 products)/Local: house  immune Benign dengue  Low  Partially reported biological,
 conditions, Public services  response,       behavioural
 infrastructure, water  herd immunity      interventions
 management, education,  nutrition, race,  Severe fever Requires High with Specialized (Passive and active) Emergency 
 social networks/ genetic traits  health servicies laboratory clinical care Incomplete control:
 Knowledge, attitudes   Fever with  support (fluid morbidity and source 
 and perceptions  hemorrhage   replacement ) mortality statistics reduction,
        insecticide
   Dengue hemorrhagic               spraying, 
   fever/dengue     social
     shock fever     mobilization
   (grades I, II, III, IV)    
          
 Challenges Pathogenesis Assessment  Risk awareness. Identification of at risk populations, Vaccine, effective 
   of WHO  Behavior  case management, laboratory and   vector control, 
   definition change clinical infrastructure  sustainable
      community
      prevention and
      interventions
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• Global determinants
Multiple factors favour viral transmission to hu-
mans by a mosquito vector: human population 
growth, rural-urban migration, and unplanned 
urbanization, characterized by the inadequacy 
of basic urban infrastructure with substandard 
housing conditions and insufficient water sup-
ply, sewage and waste management systems 19. 
In addition, the uncontrollable massive prolif-
eration of non-recyclable products (discarded 
plastic, metal and glass containers, tires) has re-
sulted in a deteriorated environment, favouring 
an increase in mosquito breeding sites.
Today, cities are better communicated by 
more and faster means of transport, thereby cre-
ating urban networks where risks are easily dis-
seminated from local to international settings. 
Population movements (migration and tourism) 
are important vehicles for spreading the sero-
types and strains, and the co-circulation of mul-
tiple serotypes increases the potential for the 
emergence of dengue hemorrhagic fever/den-
gue shock syndrome 20. Routes of global trade 
provide natural sources for vector dispersion 21, 
while a global economy means that no country 
is completely immune to the risks. 
Dengue transmission is highly concentrated 
in urban settings, especially in those below a 
certain altitude range, above an average annual 
temperature, with a high population density 
and deficient public services infrastructure 22,23. 
However widespread distribution of dengue in-
fection in rural areas is evident as surveillance 
systems and access to health services improve 
in those areas. The logistics of vector control 
strategies in disperse and low-populated areas 
is therefore complicated. The higher rates found 
in rural areas in Thailand are linked to a higher 
dependence on water storage during the dry 
season 24. Increase in dengue/dengue hemor-
rhagic fever among rural populations has also 
been observed in Central and South America, 
with similar prevalence rates in some urban 
and rural populations 25. A study from the Gulf 
coast of Mexico showed that 85% of the com-
munities reporting dengue infection during the 
1995-1998 period were rural and 65% of those 
were classified as extremely poor according to 
socioeconomic indicators 26. Despite its wide 
dispersion in rural areas, transmission primarily 
occurs in urban environments.
Ae. aegypti is an urban mosquito that is do-
mesticated where population density, proximity 
to dwellings, and large and continuous produc-
tion of breeding sites, all provide ideal condi-
tions for transmission. It is highly dependent on 
the existence of man-made artificial contain-
ers widely used to deal with deficiencies and 
inconsistencies in domestic water supply. This 
situation must be analyzed not only from the 
individual perspective but also as a social prob-
lem where every member of the community has 
a role and a responsibility. Special emphasis 
should be placed on industry’s role in produc-
ing new types of containers which may be mas-
sively introduced into the community, with no 
provision for adequate disposal. The burden of 
control strategies has shifted to the community, 
even though risk is influenced by factors that are 
external to the community’s environment. Con-
trol strategies have focused responsibility only 
on the community, without regulating the role 
of industry, and its social responsibility regard-
ing environmental health.
• Local determinants
Dengue should not be considered a poverty-re-
lated disease because it affects wealthy neigh-
bourhoods as well, although the magnitude of 
risk can be moderated by the use of housing 
materials such as screens in doors and windows 
27,28. In Taiwan, it was estimated that 63% of 
dengue infections could be eliminated if eve-
ryone lived in adequately screened homes 29. 
Even in comparable areas both with high vec-
tor abundance in an ideal climate such as the 
Mexican-Texas border, the primary determi-
nant for dengue prevalence was socioeconom-
ic. Improved housing conditions (the use of air 
conditioners) limited transmission even when 
Ae. aegypti infestation rates were remarkably 
high on both sides 30. Dengue infection rates in 
Southeast Asia have been declining, in part due 
to strong economic growth in many countries, 
and to improved housing standards and control 
programs, which have reduced vector popula-
tions 31. Dengue transmission by Ae. aegypti has 
been associated with poor hygiene, and poor 
socioeconomic and literacy levels, especially for 
female heads of households 32,33,34.
Biological risk factors
The complex relationship between climate vari-
ables, mosquito abundance, human host density, 
and viral serotype define the potential hetero-
geneity of disease transmission patterns. Vectors 
need to contact infected and susceptible hosts, 
and therefore abundance, dispersion, mortal-
ity, genetic and tissue susceptibility to infection, 
feeding behaviour, and the extrinsic incubation 
period are the most important variables for den-
gue transmission dynamics 35,36,37,38.
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Genetic analyses of dengue viruses have 
been useful to monitor the transmission of viral 
genotypes associated with the increase of severe 
cases 39. Dengue 2 (DEN-2) viruses belonging to 
the Southeast Asian genotype appear to be bet-
ter adapted to mosquito transmission and are 
associated with more severe clinical outcomes. 
They are apparently displacing the American 
genotype of DEN-2 viruses in some regions of 
Latin America 40.
Universal susceptibility to infection implies 
natural risk for all exposed populations even 
though most people suffer only mild fevers 
when infected. Severe dengue develops where 
endemic transmission and co-circulation of dif-
ferent serotypes occurs. The role of age, sex, race 
and genetic background in the host population 
interact in different ways depending on the his-
tory of dengue in each country or region. The age 
distribution of dengue hemorrhagic fever cases 
in the Americas is different from that observed 
in Asia. Cases in Cuba and Venezuela include all 
age groups, although two thirds of the fatalities 
have been in children under the age of 15. Stud-
ies in Brazil describe a mean age range of 31-
45 years. In Puerto Rico the mean age changed 
from under 15 years to 38 years between 1986 
and 1991. Nevertheless, elderly groups in Puerto 
Rico had less haemorrhagic symptoms, similar 
case fatality rates, and were hospitalized as of-
ten as infants 41.
Infection serotype and previous exposure 
history to other dengue serotypes are known to 
influence disease severity 42. Primary infection 
with any of the four dengue serotypes is usually 
associated with mild disease, while increased 
susceptibility to dengue hemorrhagic fever/
dengue shock syndrome occurs if the individual 
is infected with a second heterologous serotype. 
The immune basis for this hypothesis suggests 
that antibodies developed during the primary 
infection decline to sub-neutralizing levels 
and instead of mediating viral clearance, assist 
the new virus in infecting host macrophages, 
a phenomena known as antibody-dependent 
enhancement 43. Nevertheless, dengue hemor-
rhagic fever resulting from primary infections 
has increased over time from 1% in 1978 to 14% 
in 1997, but is associated with  milder clinical 
symptoms 44. The risk of developing dengue 
hemorrhagic fever has been estimated at only 
1-125 severe cases out of every 1,000 dengue 
infections in children 45 and it occurs 15 to 80 
times more frequently in individuals experienc-
ing a secondary infection although the reasons 
are still not clearly understood 46,47.
Health services determinants
Clinical profile
Infection with any virus serotype can produce a 
wide spectrum of clinical illness, ranging from 
asymptomatic nonspecific febrile syndrome, to 
severe and fatal hemorrhagic disease. While most 
patients go through an asymptomatic phase, 
those who have signs and symptoms develop a 
self-limiting illness considered benign that runs 
unapparent or mild in children. Dengue hem-
orrhagic fever and dengue shock syndrome are 
life-threatening illnesses associated with hemor-
rhage, thrombocytopenia and increased vascu-
lar permeability. The severe limit of the dengue 
spectrum is characterized by the sudden onset of 
hemoconcentration and hypoproteinemia and 
fever defervescence, but it has been difficult to 
adhere to the WHO case definition of hemocon-
centration in certain settings, since there is no 
precise test that can accurately predict impend-
ing dengue vascular leakage, hipovolemia and 
shock 48. An important aim of the WHO classi-
fication system is to allow prompt identification 
of patients who are at greatest risk for developing 
severe dengue complications, thereby facilitating 
triage and appropriate use of clinical resources. 
Strict application of clinical criteria, however, un-
derestimates the number of severe cases. Unfor-
tunately, the WHO definition requires multiple 
and repeated clinical tests that are not available 
in countries with limited resources. Omission of 
the tourniquet test would impede detection of 
Grade I dengue hemorrhagic fever cases that rep-
resent 15-20% of all dengue hemorrhagic fever 
cases. Even early treatment is incompatible with 
diagnostic criteria, since appropriately hydrated 
cases will not present hemoconcentration 45. In 
Nicaragua, only 30% of infants in a study fulfilled 
strict dengue hemorrhagic fever/dengue shock 
syndrome criteria and the tourniquet test had a 
low sensitivity 49. Approximately 82% of Vietnam-
ese children in shock were correctly identified 
using the narrow WHO classification system 50, 
although the tourniquet test had a sensitivity of 
only 41.6% 51. Differences between disease pat-
terns from Southeast Asia and the Americas can 
be traced to clinical practice, particularly to the 
failure of clinicians in the Americas to collect 
appropriate data to fulfil the requirements of 
the WHO case definition 52. In Asia, better case 
management and intensive national programs to 
educate parents and medical staff improved early 
care and avoidance of over hydration of dengue 
hemorrhagic fever/dengue shock syndrome pa-
tients 43.
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Risk perception and diagnosis
Dengue is not a medical priority for affected 
communities, since their social, economic and 
environmental priorities are more compelling 
than an inadvertent, mild fever solved by self 
medication which rarely requires clinical atten-
tion. At the family level, dengue is considered 
mild, and a common disease which does not 
require investment in time or money in health 
care, except when symptoms are severe. Even 
when studies have demonstrated that people 
in endemic countries recognized the disease 
and its link to the vector, control practices are 
not equivalent to knowledge about the disease 
or risk perception. In most regions, there is no 
appreciation or sense of urgency or risk associ-
ated with the worldwide deteriorating dengue 
situation. Cultural and practical issues related to 
water management at the domestic, community 
and urban levels are crucial to understanding risk 
assessment, and hence the development of ef-
fective control strategies. It is a common belief 
that control is only the responsibility of govern-
ment agencies (vector control programs), which 
undermines individual actions, and a sense of 
community responsibility 53. 
When faced with a dengue fever case, phy-
sicians require support from laboratories to 
confirm infection using paired blood samples, 
and/or to classify the stage and severity of clinical 
findings. In addition to the problem of inappro-
priate clinical diagnoses by unskilled physicians, 
there is an absence of quality serological diag-
noses and viral isolation in endemic areas. Due 
to intensive dengue transmission in the region, 
countries are compelled to strengthen their labo-
ratory capabilities in support of surveillance ac-
tivities. By 1996, only 53 laboratories in 14 coun-
tries had serologic diagnostic capabilities using 
IgM antibodies; only 20 had resources to perform 
virus isolation, and only 11 used molecular tech-
niques. Quality control performed from 1996 to 
2001 demonstrated that only 87% of laboratories 
had excellent performance in their diagnostic 
capabilities with problems ranging from the ir-
regular provision of antigens, dependency on 
the regional centers for kit distribution, different 
sensitivity among serologic tests, and the limited 
use of more specific diagnostic techniques 54.
Treatment
Dengue fever cases are usually treated with an-
tipyretic drugs and analgesics (salicylates are 
counter indicated). Due to the progressive na-
ture of the illness, repeated assessment during 
the febrile period may be necessary, with closely 
monitored intravenous fluid replacement as the 
cornerstone of severe case management. Severe 
dengue requires expert care and hospitaliza-
tion, even though the lack of clinical predictors 
of severe disease complicates diagnosis and 
timely treatment. The case fatality rate may be 
kept below 1% where skilled staff and facilities 
are available. In poor countries, it can be as high 
as 10% 55.
Surveillance
Dengue is a mandatory reportable disease that 
must be reported to the nearest epidemiol-
ogy unit. The clinical spectrum of the infection, 
however, undermines surveillance activities, 
for several reasons. First, the most cases are as-
ymptomatic and go undetected. The prevalence 
of asymptomatic children in Costa Rica varied 
from 2.9% in San Jose to 36.9% in the coastal re-
gion 56. During the 1970’s, dengue swept through 
Colombia causing an extensive epidemic where 
more than half a million cases were estimated 
but most occurred silently for most of the period. 
The silent epidemic in the city of Salvador, Brazil, 
between 1998 and 1999 was estimated to have 
infected around 560,000 individuals, while the 
official notification system only recorded 360 
cases 57. Asymptomatic cases and under-report-
ing contributed to a false panorama of dengue 
in these areas. Similar results were reported in 
central Brazil, where seroprevalence surveys es-
timated 340,000 cases and official reports only 
contained 9,544 32.
Secondly, a large proportion of infected indi-
viduals have the mild form of the disease, which is 
perceived as not serious enough to warrant health 
care assistance. Dengue cases are misdiagnosed 
by medical personnel as a febrile syndrome, and 
therefore go unreported. When dengue fever is 
identified, regulatory guidelines require paired 
blood samples to confirm diagnosis, therefore 
only a small proportion of cases are diagnosed, 
confirmed and reported. Dengue statistics in the 
region under-report mild and classic cases, and 
are not designed to recognize all but the most 
severe cases. Confirmed cases face the same 
technical caveats as all laboratory tests required 
to comply with the strict WHO classification cri-
teria. This situation explains why during 2006, 
only 4% of the total number of dengue cases were 
confirmed by laboratory tests (PAHO). 
Finally, official notification systems register 
cases reported by the primary health care system, 
which is used mainly by uninsured populations. 
The diversity of public health institutions in each 
country complicates opportune case notifica-
tion to surveillance and control programs. The 
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private health sector rarely complies with case 
notification, and consequently, important data 
is lost from a variety of health providers. Com-
bined, these undermine coverage and access to 
the surveillance system. A dengue prevention 
program faces multiple operational problems 
due to the lack of sensitive identification of at-
risk populations, and identification of infected 
versus diseased patients. 
Prevention and control
Ae. aegypti is adapted to domestic and perido-
mestic environments, and breeds in different 
types of artificial containers, which are specifi-
cally used for water storage due to insufficient 
municipal supply. Even in areas with a continu-
ous potable water supply, Ae. aegypti densities 
can be found in clean containers such as flower 
vases and fountains. Traditional entomological 
indices such as House or Premise Index (HI), 
Container Index (CI) and Breteau Index (BI), are 
used to monitor Ae. aegypti, although attempts 
to associate them with dengue transmission have 
failed due to the fact that these indices measure 
prevalence, not abundance, and because they do 
not discriminate between capacity or productiv-
ity. Other indices have been proposed to address 
the issue of productivity (Larval Density Index, 
the Stegomyia Index and the Stegomyia Larval 
Density Index), but are labor intensive and im-
practical 58. Pupal surveillance of Aedes vectors 
has been proposed as a more accurate measure 
of female mosquitoes as complementary to tra-
ditional larval surveillance. The Premise Condi-
tion Index offers a rapid assessment method of 
selected households for surveys, does not require 
larval identification or infested container and 
larval counts, and can be done from the outside 
and is quick. Its primary limitation is that it does 
not consider indoor breeding risks 59.
While source reduction is considered the 
most effective measure of vector control, it is im-
portant to distinguish sources that are controlla-
ble from those that are disposable, and those that 
are indoors versus outdoors. In Singapore, 79% of 
total breeding sites were indoors 29. In Fiji, sur-
veillance and control strategies failed to define 
key container types, e.g. tyres and drums, which 
were responsible for most of the Aedes being pro-
duced 60. Studies in El Salvador have demonstrat-
ed that infested discarded cans, plastic contain-
ers and tire casings were risk factors for dengue 
infection with abundance-attributable fractions 
of 4%, 13% and 31%, respectively 61.
Reduction of mosquito breeding in house-
hold water containers using larvicides, predatory 
crustaceans, or elimination of discarded contain-
ers, and control of adult mosquitoes by spraying 
insecticides, requires continuous efforts by the 
communities, which are difficult to sustain, and 
for which effectiveness requires validation. Op-
tions for control, such as insecticide-treated win-
dow curtains, water container covers and con-
trolled-release insect growth regulators may con-
tribute to reduce densities of dengue vectors and 
dengue transmission 62. Decreasing the carrying 
capacity of the mosquito’s environment using 
frequent reduction of the vector breeding sites 
seems to be the most effective way to control dis-
ease but good entomological indices are required 
to monitor transmission risk, and evaluate the 
impact of different control strategies, whether 
physical, biological, chemical or behavioural.
Our ability to control Ae. aegypti is also lim-
ited since larvicides have low coverage in terms 
of the large pool of breeding sites present in any 
urban environment. Growing reluctance on the 
part of residents to accept their use in potable 
water, their expense, the increase in non essen-
tial water holding containers in the environment, 
and the increasing frequency of locked residenc-
es during the day has resulted in infrequent ap-
plications and inadequate coverage which affect 
long-term suppression 63. Insecticides are short 
in reach when it comes to effective penetration 
into the vector’s resting places, and they are short 
lived in relation to female adult mortality. Stud-
ies conducted in Asia and the Americas, indicate 
that after the application of Ultra Low Volume 
(ULV), the adult population of mosquitoes re-
turned to pretreatment levels within two weeks, 
and even with multiple applications, the impact 
on incidence was minimal 64. 
Aside from these technical problems, there 
is no public health program with sufficient hu-
man resources to deal with all households in ur-
ban centers (short response capacity). National 
programs are under-funded, poorly managed 
and operate in isolation from other health care 
delivery elements. Field workers are poorly 
motivated and supervised, are underpaid and 
lack communication skills. Unfortunately, dur-
ing low transmission periods, most individuals 
as well as government agencies lose interest in 
mosquito control, and hence subsequent vec-
tor population increases. Dengue control has 
been approached as a community responsibil-
ity by the public health community, and exclu-
sive reliance on the community to assume full 
responsibility for vector control activities has 
been stressed even though it is a problem which 
requires resources and financing from different 
governmental agencies and municipal actors 
outside the health sector.
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The domestic urban environment creates 
new risks associated with accelerated urban-
ization processes and this risk challenges the 
countries to respond with basic sanitary infra-
structure. Intersectoral and multidisciplinary 
vector control programs are needed and several 
community based dengue control interventions 
have been reported from a wide variety of eco-
logical and social environments, including: com-
munication campaigns, educational initiatives, 
behavioral change, biological control efforts, 
integrated control projects and a mixture of the 
above strategies. Interventions that rely on edu-
cational strategies only, have less impact on be-
havior and entomologic indices 65. The evidence 
to show that community-based dengue control 
programmes alone, or those implemented in 
combination with institutional control activities, 
can enhance the effectiveness of dengue control 
programmes is weak 66.
Behavioral changes can help reduce the in-
festation of domestic containers, if individual 
community and institutional practices are cor-
rectly targeted. Changing behavior requires mo-
bilizing social networks and organizations, as 
well as implementing firm public policies. A new 
relationship between governmental institutions 
and individuals is required and programs should 
be designed based on local sanitation structure, 
as well as community organization and roles 
for different family members. Programs should 
incorporate epidemiological surveillance, com-
munity participation, management of the envi-
ronment and basic public services, case manage-
ment, education, and effective vector control and 
training. Sustained dengue control requires part-
nerships among donors, the public sector, civil 
society, non-governmental organizations, the 
private sector, and the interactions between poli-
ticians, public health personnel, administrators, 
engineers, urban planners, and environmental 
groups, in order to strengthen existing intersec-
toral management structures in support of com-
munity actions 67,68.
Challenges
Countries in the Americas now face the irrefut-
able fact that social, economic and environmen-
tal conditions have converged to establish den-
gue as a major health threat to their populations. 
The enormous investment required for urban in-
frastructure in developing countries, will hardly 
be available in the near future, although adapta-
tion of health services to avoid or prevent den-
gue transmission is feasible. Basic research must 
provide a better understanding of the immune 
response, the antibody dependent enhancement 
mechanisms, virulence factors for the different 
genotypes and pathogenic pathways of severe 
dengue infection. Understanding the changing 
and severe clinical profile of dengue infection 
must be clarified for the development of safe 
vaccines and effective drugs for treatment. Clini-
cal diagnoses of dengue cases will benefit and 
improve the identification of at-risk populations 
for severe dengue, although a strong laboratory-
based surveillance system, intensive training of 
medical staff and strong medical infrastructure 
support for clinical diagnosis in endemic and 
high risk areas are also essential components. 
Without vaccines, effective drugs, or sensitive 
diagnostic tests, the only available response to 
reduce disease severity and case fatality is clinical 
management through enhanced care supported 
by accessible, sensitive and specific useful diag-
nostic tests. These tools will help identify warn-
ing signs for severe disease and evidenced-based 
criteria for treatment procedures standardiza-
tion 69. The current WHO/dengue hemorrhagic 
fever definition is an epidemiological tool to col-
lect public health data on the incidence of symp-
tomatic infection, as well as disease severity. This 
definition should be simple and reproducible, use 
readily available information, and should be ap-
plicable to the majority of cases without modifi-
cation or reinterpretation. The current definition 
is not equally useful in all clinical care or epide-
miological situations, nor does it reflect current 
practices in case treatment, hospital laboratory, 
and diagnostic methods 43.
An ideal dengue vaccine must be tetravalent, 
in order to protect against infection from all four 
serotypes. Recent initiatives focus predominant-
ly on recombinant strategies based on infectious 
clone technology, DEN antigen-encoding viral 
and plasmid vectors and recombinant DEN anti-
gens. Several multivalent dengue vaccines are in 
various stages of development, but none is close 
to regulatory approval. Live attenuated tetrava-
lent dengue vaccines are being developed either 
through multiple passages of the virus in animal 
tissues and for cell culture, or through viral mu-
tation combined with chimerization. The risk of 
developing severe dengue during a secondary 
infection has major implications for vaccination 
policy, since vaccines developed against one or 
two strains could theoretically prime populations 
for future epidemics of dengue hemorrhagic fe-
ver/dengue shock syndrome 70. The potential for 
immunization-mediated enhanced disease has 
given rise to the current goal, which is to produce 
solid immunity against all four serotypes with 
one or two vaccine doses. Once a safe vaccine 
becomes available for wide-scale evaluation, it 
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needs to be tested to measure protective efficacy 
and safety, since a major problem will be to dif-
ferentiate potential vaccine-induced immune 
enhancement diseases. The 50 million dollars of 
support granted by the Bill and Melinda Gates 
Foundation to develop a paediatric dengue vac-
cine does not necessarily guarantee that a vac-
cine may be available for poor children in dengue 
endemic countries in the near future 71.
The development of improved entomological 
surveillance methods is crucial for timely vec-
tor control. Entomological indices must measure 
transmission risk thresholds and provide pre-
cise information to evaluate physical, biological, 
chemical or behavioural interventions. Breeding 
containers must be identified according to their 
abundance, potential productivity and control 
activities required for elimination of breeding 
risks (controllable vs. disposable). Productiv-
ity of key premises or breeding containers is an 
important issue since a low proportion of posi-
tive premises and containers are responsible for 
high productivity. As a result, limited resources 
are available to control high risk areas 72. Effec-
tive vector control should be based on timely 
detection of entomological risks which can then 
be tackled through community participation 
schemes supported by governmental actors and 
social stakeholders.
Community based health projects need to 
find the ingredients necessary to generate a con-
tinuous action to promote changes in behavior 
since they are expected to modify the environ-
ment where the problem arises. Sustainability 
provides an additional difficulty for all strategies, 
because it requires not only continuity of actions, 
but also effectiveness. Although most commu-
nity-based interventions emphasize this impact 
on behavioral changes of individuals, families 
and groups, they must also provoke changes in 
the behavior and responsibilities of institutions 
(health, education, municipal authorities, etc.) 
and other stakeholders. It is necessary to stress 
that preventive practices for dengue control, can 
only be modified or present when they are sup-
ported by efficient urban infrastructure. 
Dengue is a complex disease that threatens 
the lives of millions of people in developing 
countries. Imprecise morbidity and mortality 
statistics undermine the study of factors asso-
ciated with dengue transmission and its rec-
ognition as a major regional health problem. 
Dengue is perceived as a problem of “others” 
(individually, collectively and institutionally), 
and therefore responsibility for its control is 
passed on to others (neighbors, the community, 
municipality, health institution or other govern-
mental agencies) and not fully appropriated by 
any. With no consistent or precise risk indicators 
(clinical, entomological, and epidemiological), 
there is little opportunity for timely diagnoses, 
treatment, health interventions or vector con-
trols (poor surveillance). Solutions targeting on-
ly the vector reduce the impact of interventions. 
With ineffective interventions, there is no sus-
tainable control and without population-based 
and political commitment, there are insufficient 
resources to address the problem.
Resumen
El dengue es la enfermedad transmitida por vector 
más importante en las Américas, que amenaza la vi-
da de millones de personas. Las cifras subestiman la 
magnitud del problema y el dengue no figura como 
prioridad para las autoridades en salud y no se iden-
tifica como problema (baja percepción de riesgo), por 
lo que las medidas para el control se realizan tardía-
mente. El dengue se considera un problema de “otros” 
(individuo, colectividad, institucional) y la respon-
sabilidad del control se desvía hacia otros (vecindario, 
comunidad, municipio, el Ministerio de Salud, etc.). Se 
carece de indicadores de riesgo precisos, por lo que no 
hay oportunidad para acciones de diagnóstico, trata-
miento, prevención y control vectorial. Con interven-
ciones poco efectivas no hay control sostenible y sin 
compromiso político no hay recursos suficientes para 
enfrentar este problema sanitario. Este artículo aborda 
los desafíos para la prevención y el control del dengue 
en las Américas.
Dengue; Control de Enfermedades Transmisibles; Pre-
vención de Enfermedades
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